Click here to get full coverage on Akebia Therapeutics (AKBA) awards RSUs and stock options to director Adams - Stock Titan

Akebia Therapeutics (AKBA) awards RSUs and stock options to director Adams  Stock Titan

Akebia Therapeutics (AKBA) awards RSUs and stock options to director Adams - Stock Titan

Click here to get full coverage on Akebia Therapeutics, Inc.(NasdaqCM:AKBA) dropped from S&P Biotechnology Select Industry Index - marketscreener.com

Akebia Therapeutics, Inc.(NasdaqCM:AKBA) dropped from S&P Biotechnology Select Industry Index  marketscreener.com

Akebia Therapeutics, Inc.(NasdaqCM:AKBA) dropped from S&P Biotechnology Select Industry Index - marketscreener.com

Click here to get full coverage on Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results - simplywall.st

Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results  simplywall.st

Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results - simplywall.st

Click here to get full coverage on Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results - Yahoo Finance

Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results  Yahoo Finance

Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results - Yahoo Finance

Click here to get full coverage on Akebia Therapeutics (AKBA) Proxy filing Summary - Quartr

Akebia Therapeutics (AKBA) Proxy filing Summary  Quartr

Akebia Therapeutics (AKBA) Proxy filing Summary - Quartr

Click here to get full coverage on $AKBA stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

$AKBA stock is down 11% today. Here's what we see in our data.  Quiver Quantitative

$AKBA stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Akebia Therapeutics (AKBA) grants RSUs and stock options to director Rogers - Stock Titan

Akebia Therapeutics (AKBA) grants RSUs and stock options to director Rogers  Stock Titan

Akebia Therapeutics (AKBA) grants RSUs and stock options to director Rogers - Stock Titan

Click here to get full coverage on How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates - Yahoo Finance

How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates  Yahoo Finance

How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates - Yahoo Finance

Click here to get full coverage on Akebia (NASDAQ: AKBA) director Myles Wolf granted RSUs and options - Stock Titan

Akebia (NASDAQ: AKBA) director Myles Wolf granted RSUs and options  Stock Titan

Akebia (NASDAQ: AKBA) director Myles Wolf granted RSUs and options - Stock Titan

Click here to get full coverage on Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan - simplywall.st

Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan  simplywall.st

Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan - simplywall.st

Click here to get full coverage on Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates  Yahoo Finance

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings - Quiver Quantitative

AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings  Quiver Quantitative

AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings - Quiver Quantitative

Click here to get full coverage on Akebia Therapeutics (AKBA) director receives RSU and stock option grants - Stock Titan

Akebia Therapeutics (AKBA) director receives RSU and stock option grants  Stock Titan

Akebia Therapeutics (AKBA) director receives RSU and stock option grants - Stock Titan

Click here to get full coverage on [Form 4] Akebia Therapeutics, Inc. Insider Trading Activity - Stock Titan

[Form 4] Akebia Therapeutics, Inc. Insider Trading Activity  Stock Titan

[Form 4] Akebia Therapeutics, Inc. Insider Trading Activity - Stock Titan

Click here to get full coverage on Akebia (AKBA) director Cynthia Smith granted RSUs and options for board service - Stock Titan

Akebia (AKBA) director Cynthia Smith granted RSUs and options for board service  Stock Titan

Akebia (AKBA) director Cynthia Smith granted RSUs and options for board service - Stock Titan

Click here to get full coverage on Akebia Therapeutics (NASDAQ: AKBA) investors back share increase and executive pay - Stock Titan

Akebia Therapeutics (NASDAQ: AKBA) investors back share increase and executive pay  Stock Titan

Akebia Therapeutics (NASDAQ: AKBA) investors back share increase and executive pay - Stock Titan

Click here to get full coverage on Kidney disease-focused Akebia to present at NY healthcare conference - Stock Titan

Kidney disease-focused Akebia to present at NY healthcare conference  Stock Titan

Kidney disease-focused Akebia to present at NY healthcare conference - Stock Titan

Click here to get full coverage on In dialysis anemia, Vafseo beat darbepoetin on deaths-plus-hospitalizations - Stock Titan

In dialysis anemia, Vafseo beat darbepoetin on deaths-plus-hospitalizations  Stock Titan

In dialysis anemia, Vafseo beat darbepoetin on deaths-plus-hospitalizations - Stock Titan

Click here to get full coverage on State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia - Stock Titan

State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia  Stock Titan

State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia - Stock Titan

Click here to get full coverage on Akebia Therapeutics (AKBA) Losses Narrow To US$9.1 Million Challenging Bearish Profitability Narratives - simplywall.st

Akebia Therapeutics (AKBA) Losses Narrow To US$9.1 Million Challenging Bearish Profitability Narratives  simplywall.st

Akebia Therapeutics (AKBA) Losses Narrow To US$9.1 Million Challenging Bearish Profitability Narratives - simplywall.st

Click here to get full coverage on Why The Narrative Around Akebia Therapeutics (AKBA) Is Shifting After New Valuation Reset - Yahoo Finance

Why The Narrative Around Akebia Therapeutics (AKBA) Is Shifting After New Valuation Reset  Yahoo Finance

Why The Narrative Around Akebia Therapeutics (AKBA) Is Shifting After New Valuation Reset - Yahoo Finance

Click here to get full coverage on AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction  Stocktwits

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits

Click here to get full coverage on Akebia (AKBA) Q1 2026 Earnings Transcript - The Motley Fool

Akebia (AKBA) Q1 2026 Earnings Transcript  The Motley Fool

Akebia (AKBA) Q1 2026 Earnings Transcript - The Motley Fool

Click here to get full coverage on Akebia Therapeutics (AKBA) Jefferies Global Healthcare Conference 2026 Summary - Quartr

Akebia Therapeutics (AKBA) Jefferies Global Healthcare Conference 2026 Summary  Quartr

Akebia Therapeutics (AKBA) Jefferies Global Healthcare Conference 2026 Summary - Quartr

Click here to get full coverage on Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner  Yahoo Finance

Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $AKBA Given $4 Price Target - Quiver Quantitative

New Analyst Forecast: $AKBA Given $4 Price Target  Quiver Quantitative

New Analyst Forecast: $AKBA Given $4 Price Target - Quiver Quantitative

Click here to get full coverage on Akebia Therapeutics Inc (AKBA) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance

Akebia Therapeutics Inc (AKBA) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...  Yahoo Finance

Akebia Therapeutics Inc (AKBA) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance

Click here to get full coverage on In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions - simplywall.st

In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions  simplywall.st

In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions - simplywall.st

Click here to get full coverage on Akebia executives head to New York for Apr. 14 biotech investor meetings - Stock Titan

Akebia executives head to New York for Apr. 14 biotech investor meetings  Stock Titan

Akebia executives head to New York for Apr. 14 biotech investor meetings - Stock Titan

Click here to get full coverage on AKBA: Vafseo growth accelerates, pipeline advances, and broad access expected post-2026 - TradingView

AKBA: Vafseo growth accelerates, pipeline advances, and broad access expected post-2026  TradingView

AKBA: Vafseo growth accelerates, pipeline advances, and broad access expected post-2026 - TradingView

Click here to get full coverage on How Low Can Akebia Therapeutics Stock Really Go? - Trefis

How Low Can Akebia Therapeutics Stock Really Go?  Trefis

How Low Can Akebia Therapeutics Stock Really Go? - Trefis

Click here to get full coverage on Akebia Therapeutics Inc (AKBA) Institutional Confidence - TradingKey

Akebia Therapeutics Inc (AKBA) Institutional Confidence  TradingKey

Akebia Therapeutics Inc (AKBA) Institutional Confidence - TradingKey

Click here to get full coverage on Akebia starts human testing of drug for kidney injury after heart surgery - Stock Titan

Akebia starts human testing of drug for kidney injury after heart surgery  Stock Titan

Akebia starts human testing of drug for kidney injury after heart surgery - Stock Titan

Click here to get full coverage on Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  GlobeNewswire

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Click here to get full coverage on Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients - Yahoo Finance

Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients  Yahoo Finance

Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients - Yahoo Finance

Click here to get full coverage on AKBA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

AKBA Financials: Income Statement, Balance Sheet & Cash Flow  Stock Titan

AKBA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Click here to get full coverage on Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Yahoo Finance

Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)  Yahoo Finance

Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Yahoo Finance

Click here to get full coverage on Why Is Akebia (AKBA) Up After Strong Vafseo Data and Surging Q3 2025 Revenue? - Yahoo Finance

Why Is Akebia (AKBA) Up After Strong Vafseo Data and Surging Q3 2025 Revenue?  Yahoo Finance

Why Is Akebia (AKBA) Up After Strong Vafseo Data and Surging Q3 2025 Revenue? - Yahoo Finance

Click here to get full coverage on Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA) - Seeking Alpha

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA)  Seeking Alpha

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA) - Seeking Alpha

Click here to get full coverage on Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook - simplywall.st

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook  simplywall.st

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook - simplywall.st

Click here to get full coverage on A Look at Akebia Therapeutics (AKBA) Valuation Following Q3 Profit and New Vafseo Clinical Data - simplywall.st

A Look at Akebia Therapeutics (AKBA) Valuation Following Q3 Profit and New Vafseo Clinical Data  simplywall.st

A Look at Akebia Therapeutics (AKBA) Valuation Following Q3 Profit and New Vafseo Clinical Data - simplywall.st

Click here to get full coverage on Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights - GlobeNewswire

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights  GlobeNewswire

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights - GlobeNewswire

Click here to get full coverage on The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance

The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts  Yahoo Finance

The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance

Click here to get full coverage on Three kidney disease programs take center stage at Akebia's April 2 R&D Day - Stock Titan

Three kidney disease programs take center stage at Akebia's April 2 R&D Day  Stock Titan

Three kidney disease programs take center stage at Akebia's April 2 R&D Day - Stock Titan

Click here to get full coverage on Akebia plunges 20% on muted Q1 print - Seeking Alpha

Akebia plunges 20% on muted Q1 print  Seeking Alpha

Akebia plunges 20% on muted Q1 print - Seeking Alpha

Click here to get full coverage on Biotech Akebia hands new hires stock options at $1.31 a share - Stock Titan

Biotech Akebia hands new hires stock options at $1.31 a share  Stock Titan

Biotech Akebia hands new hires stock options at $1.31 a share - Stock Titan

Click here to get full coverage on Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio - GlobeNewswire

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio  GlobeNewswire

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio - GlobeNewswire

Click here to get full coverage on H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo

H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6  Moomoo

H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Click here to get full coverage on Akebia (AKBA) Reports Strong Q4 Revenue and Positive Outlook for Vafseo - GuruFocus

Akebia (AKBA) Reports Strong Q4 Revenue and Positive Outlook for Vafseo  GuruFocus

Akebia (AKBA) Reports Strong Q4 Revenue and Positive Outlook for Vafseo - GuruFocus

Click here to get full coverage on Akebia Therapeutics, Inc. (NASDAQ:AKBA) most popular amongst individual investors who own 55% of the shares, institutions hold 43% - Yahoo Finance

Akebia Therapeutics, Inc. (NASDAQ:AKBA) most popular amongst individual investors who own 55% of the shares, institutions hold 43%  Yahoo Finance

Akebia Therapeutics, Inc. (NASDAQ:AKBA) most popular amongst individual investors who own 55% of the shares, institutions hold 43% - Yahoo Finance

Click here to get full coverage on AKBA: Strong 2025 revenue growth and improved margins set the stage for Vafseo-led expansion in 2026 - TradingView

AKBA: Strong 2025 revenue growth and improved margins set the stage for Vafseo-led expansion in 2026  TradingView

AKBA: Strong 2025 revenue growth and improved margins set the stage for Vafseo-led expansion in 2026 - TradingView

Click here to get full coverage on Boswellia extract delivers next-level joint comfort - Nutraceutical Business Review

Boswellia extract delivers next-level joint comfort  Nutraceutical Business Review

Boswellia extract delivers next-level joint comfort - Nutraceutical Business Review

Click here to get full coverage on Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy - Insider Monkey

Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy  Insider Monkey

Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy - Insider Monkey

Click here to get full coverage on Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment? - simplywall.st

Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment?  simplywall.st

Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment? - simplywall.st

Click here to get full coverage on Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights - Yahoo Finance

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights  Yahoo Finance

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights - Yahoo Finance

Click here to get full coverage on From bench to bedside, boswellic acids in anti-inflammatory therapy — mechanistic insights, bioavailability challenges, and optimization approaches - Frontiers

From bench to bedside, boswellic acids in anti-inflammatory therapy — mechanistic insights, bioavailability challenges, and optimization approaches  Frontiers

From bench to bedside, boswellic acids in anti-inflammatory therapy — mechanistic insights, bioavailability challenges, and optimization approaches - Frontiers

Click here to get full coverage on Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript - Insider Monkey

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript  Insider Monkey

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks - Yahoo Finance

Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks  Yahoo Finance

Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks - Yahoo Finance

Click here to get full coverage on InvestingPro’s overvalued call on Akebia proved right as stock tumbled 44% By Investing.com - Investing.com

InvestingPro’s overvalued call on Akebia proved right as stock tumbled 44% By Investing.com  Investing.com

InvestingPro’s overvalued call on Akebia proved right as stock tumbled 44% By Investing.com - Investing.com

Click here to get full coverage on Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights - Yahoo Finance

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights  Yahoo Finance

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights - Yahoo Finance

Click here to get full coverage on This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? - Yahoo Finance

This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?  Yahoo Finance

This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? - Yahoo Finance

Click here to get full coverage on Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates  TradingKey

Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Click here to get full coverage on Is the Options Market Predicting a Spike in Akebia Therapeutics Stock? - TradingView

Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?  TradingView

Is the Options Market Predicting a Spike in Akebia Therapeutics Stock? - TradingView

Click here to get full coverage on Akebia Therapeutics Inc (AKBA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Akebia Therapeutics Inc (AKBA) Valuation: PE, PB & Fair Value Analysis  TradingKey

Akebia Therapeutics Inc (AKBA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Click here to get full coverage on Akebia Therapeutics Inc (AKBA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Akebia Therapeutics Inc (AKBA) Technical Analysis: Support, Resistance, Indicators & Moving Averages  TradingKey

Akebia Therapeutics Inc (AKBA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Click here to get full coverage on Akebia Therapeutics Inc (AKBA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Akebia Therapeutics Inc (AKBA) Financial Health: Profitability & Balance Sheet Analysis  TradingKey

Akebia Therapeutics Inc (AKBA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Click here to get full coverage on Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution  TradingKey

AKBA

Price Chart

Key Statistics

Technicals

About AKBA

Latest News

Akebia Therapeutics (AKBA) awards RSUs and stock options to director Adams - Stock Titan

Akebia Therapeutics, Inc.(NasdaqCM:AKBA) dropped from S&P Biotechnology Select Industry Index - marketscreener.com

Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results - simplywall.st

Advanced Charts

Top Gainers

Top Losers